Archives
-
Canagliflozin Hemihydrate: Research Workflows
2026-09-18
Canagliflozin hemihydrate gives researchers a practical SGLT2-focused tool for glucose metabolism research, while a recent sensitized-yeast study helps define what this compound does not do: inhibit TOR under the tested conditions. This article translates that distinction into assay design, preparation guidance, comparative experiments, and troubleshooting decisions.
-
8-Chloroadenosine for RNA Workflow Control
2026-09-17
Use 8-Chloroadenosine as a controllable RNA synthesis inhibitor to separate transcriptional effects from RNA stability, especially in lncRNA and cytokine workflows. This practical guide combines DMSO handling, pulse-treatment design, decay assays, and orthogonal validation for molecular biology and cancer research.
-
Mestranol, Lysosomal Stress, and Zebrafish Microglia
2026-09-17
The reference study identifies mestranol as an inducer of a reversible lysosomal storage–like state in zebrafish microglia, separating impaired intracellular digestion from defects in phagocytic uptake, cell number, or neuronal apoptosis. Its live-animal imaging, cargo-clearance assays, transcriptomics, and TFEC rescue experiments establish a useful model for studying acquired microglial lysosomal stress and environmental estrogen-associated neuroimmunotoxicity.
-
DNase I (RNase-free) in Translational Neurobiology
2026-09-16
Translational studies increasingly combine human tissue electrophysiology with RNA, RT-PCR, chromatin, and biomarker workflows. This article explains how controlled DNA digestion can protect interpretation without being mistaken for a biological intervention. It connects the cation-dependent mechanism of DNase I (RNase-free) with practical sample preparation, competitive workflow decisions, and the human DRG findings reported for tomivosertib in neuropathic pain research.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-09-16
The reference preprint shows that selected kinase inhibitors can do more than occupy the p38α active site: they can reshape its activation loop and accelerate dephosphorylation by the PPM phosphatase WIP1. Biochemical assays and X-ray structures provide a mechanistic framework for designing inhibitors that combine catalytic blockade with phosphatase-assisted pathway shutdown.
-
EZ Cap™ Mouse CD252(OX40L) mRNA: Assay Logic
2026-09-15
Explore how EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) enables controlled studies of OX40L-mediated immune co-stimulation. This article connects clinical mRNA dendritic-cell evidence with rigorous mechanistic assay design while clarifying what the literature does—and does not—validate.
-
Bestatin Inhibition of Leucine Aminopeptidase
2026-09-15
The reference study combined high-resolution X-ray crystallography of native and Bestatin-bound bovine lens leucine aminopeptidase to explain how a slow-binding inhibitor engages a dinuclear zinc active site. Its structure-based model connects Bestatin binding with a tetrahedral hydrolysis intermediate, providing a mechanistic framework for aminopeptidase activity measurement and rational inhibitor analysis.
-
UTP Solution: From RNA Substrate to Assay Signal
2026-09-14
UTP Solution (100 mM) supports controlled RNA synthesis while helping researchers distinguish reagent performance from biological regulation. This article connects nucleotide handling to the TRIM66 olfactory receptor study and practical assay design across transcription, amplification, siRNA synthesis, and metabolism.
-
Atorvastatin: HMG-CoA Reductase Inhibitor Workflows
2026-09-14
Atorvastatin connects mevalonate-pathway inhibition with practical assays for cholesterol metabolism, vascular phenotypes, and ferroptosis-oriented cancer research. This workflow-focused guide covers dosing, controls, cross-domain interpretation, and troubleshooting for reproducible preclinical experiments.
-
Indometacin Sodium: From COX to Assay Design
2026-09-13
Indometacin Sodium is more than a conventional COX inhibitor: its salt chemistry, prostaglandin synthesis inhibition, and Wnt/β-catenin activity create a framework for better assay design. This guide connects clinical evidence with inflammation, pain-signaling, and remyelination research while clarifying dose translation and experimental limitations.
-
Mecamylamine Hydrochloride: Assay Design
2026-09-12
Mecamylamine hydrochloride provides a mechanistic tool for testing nicotinic contributions to gut-brain cholinergic signaling. This article translates recent Bacteroides fragilis epilepsy findings into practical assay decisions while defining the compound’s limits in neuropsychiatric disorder research.
-
Annexin V-Cy5 in Reversible Microglial Stress
2026-09-11
A translational framework for using Annexin V-Cy5 apoptosis detection to distinguish genuine cell death from reversible lysosomal dysfunction in microglial neuroimmunotoxicity models.
-
Ibrexafungerp Against Resistant Candida auris
2026-09-11
The reference study shows that ibrexafungerp, also known as MK 3118, retains consistent in vitro activity against fluconazole-resistant Candida auris and improves outcomes in a neutropenic mouse model when treatment is initiated after infection is established. Its combination of glucan-synthase targeting, oral administration, and activity in an invasive infection model supports further investigation against drug-resistant candidiasis, while the model design also defines important limits for clinical translation.
-
KN-62: Selective CaMKII Inhibitor Guide
2026-09-10
KN-62, also known as 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, is a research inhibitor of CaMKII with a reported Ki of 0.9 μM. Product data support applications in calcium signaling, secretion, glucose transport, and K562 cell-cycle studies, while the cited social-memory study provides biological context but does not test KN-62 directly.
-
Exendin-4 Workflows for Diabetes Research
2026-09-10
Build stronger beta-cell, cAMP, insulin-sensitivity, and hepatic-steatosis assays with Exendin-4, also known as Exenatide. This practical guide connects controlled peptide experiments with a 2024 yeast-expression strategy while separating validated findings from workflow recommendations.